{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:54:57Z","timestamp":1791089697911,"version":"4.1.0"},"reference-count":23,"publisher":"King Faisal Specialist Hospital and Research Centre","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Saudi Med"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Vaso-occlusive crisis (VOC) is the leading cause of emergency department (ED) visits and hospitalization in sickle cell disease (SCD). Standardized clinical pathways may improve care quality and reduce healthcare utilization, yet regional evidence from Saudi Arabia remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVES:<\/jats:title>\n                    <jats:p>To evaluate the clinical and economic impact of a multidisciplinary clinical pathway on VOC management, opioid prescribing, and direct healthcare costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DESIGN:<\/jats:title>\n                    <jats:p>Retrospective before-and-after cohort study<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SETTING:<\/jats:title>\n                    <jats:p>Single-center, 500-bed tertiary referral hospital in Jeddah, Saudi Arabia<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS:<\/jats:title>\n                    <jats:p>Adults (\u226512 years) with confirmed SCD (HbSS, HbSC, or HbS\/\u03b2-thalassemia) presenting with isolated VOC were included. Outcomes were compared across two consecutive 12-month periods before (May 2016\u2013April 2017) and after (May 2017\u2013April 2018) pathway implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MAIN OUTCOME MEASURES:<\/jats:title>\n                    <jats:p>Annual ED visits, hospital admissions, 7-day readmission rate, opioid consumption, length of stay, and direct cost savings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SAMPLE SIZE:<\/jats:title>\n                    <jats:p>316 unique patients pre-implementation and 374 post-implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      VOC-related ED visits decreased by 69.7% (14,273 vs. 4,319;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;.001), hospital admissions by 32.9% (520 vs. 349;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;.001), and 7-day readmissions by 69.5% (151 vs. 46;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;.001); the readmission rate fell from 29.1% to 13.2%. Median length of stay decreased from 11.0 to 4.3 days. Meperidine and tramadol utilization declined significantly, whereas morphine use increased by 41.2%. When standardized to oral morphine milligram equivalents, total opioid burden nonetheless decreased by 21.8% overall (33.9% per patient-year). Annual direct cost savings totaled 410 709 Saudi Riyals.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Implementation of a multidisciplinary VOC clinical pathway was associated with substantial reductions in healthcare utilization, hospital stay, readmissions, and direct costs, while promoting evidence-based opioid prescribing in adults with SCD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LIMITATIONS:<\/jats:title>\n                    <jats:p>Single-center, uncontrolled before-and-after design without adjustment for genotype imbalance between cohorts; incomplete pathway adherence in some clinical areas; patient-reported outcomes were not collected.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5144\/0256-4947.2026.319","type":"journal-article","created":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:44:41Z","timestamp":1791089081000},"page":"319-338","source":"Crossref","is-referenced-by-count":0,"title":["Clinical pathway implementation for adult sickle cell vaso-occlusive crises: Impact on healthcare utilization, opioid prescribing, and costs"],"prefix":"10.5144","volume":"46","author":[{"given":"Ahmed M.","family":"Alhartani","sequence":"first","affiliation":[{"name":"From the Department of Pharmacy, Narcotics and Controlled Substances, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5142-0588","authenticated-orcid":true,"given":"Lenah S.","family":"Binmahfouz","sequence":"additional","affiliation":[{"name":"From the Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Alhazmi","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, Department of Medicine, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aseel","family":"Jambi","sequence":"additional","affiliation":[{"name":"From the Department of Continuous Quality Improvement and Patient Safety, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3134","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1630994"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.4103\/0256-4947.81540"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jegh.2011.06.002"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jegh.2017.12.001"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-03074-z"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.304.6840.1478"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12879"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.10517"},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","unstructured":"Tung I. 6699 Sickle cell disease: managing acute painful episodes in hospital. In: Quality Improvement and Patient Safety [Internet]. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health; 2024 [cited 2026 Jun 24]. p. A403.1\u2013A403. Available from: https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2024-rcpch.633 doi: 10.1136\/archdischild-2024-rcpch.633","DOI":"10.1136\/archdischild-2024-rcpch.633"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04193.x"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjqs-2013-001862"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001851"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","unstructured":"Pereira J ChB M Lawlor P Vigano A Dorgan M Bruera E. Equianalgesic Dose Ratios for Opioids: A Critical Review and Proposals for Long-Term Dosing. Vol. 22. 2001;22(2):672\u2013687. doi: 10.1016\/s0885-3924(01)00294-9","DOI":"10.1016\/s0885-3924(01)00294-9"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7103a1"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2020.08.007"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/JHQ.0000000000000292"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/acem.14805"},{"key":"e_1_3_4_19_2","unstructured":"Yasaei R Rosani A Saadabadi A. Meperidine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 [cited 2026 Jun 25]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470362\/ PubMed PMID: 29261967."},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.53022\/oarjms.2022.4.2.0110"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2026.1730036"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.5144\/0256-4947.2025.190"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.69268"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjqs-2015-004411"}],"container-title":["Annals of Saudi Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:44:52Z","timestamp":1791089092000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.annsaudimed.net\/doi\/10.5144\/0256-4947.2026.319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.5144\/0256-4947.2026.319"],"URL":"https:\/\/doi.org\/10.5144\/0256-4947.2026.319","relation":{},"ISSN":["0256-4947","0975-4466"],"issn-type":[{"value":"0256-4947","type":"print"},{"value":"0975-4466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}